Title:
がん抗原ペプチド
Document Type and Number:
Japanese Patent JP6857930
Kind Code:
B2
Abstract:
The disclosure provides a peptide consisting of 10 to 45 amino acids and comprising the amino acid sequence of KILQQSRIVQX, wherein X is absent or S; an amino acid sequence of 10 or more contiguous amino acids in the amino acid sequence of DVQKIVESQINFHGKKLKLGPAIRKQNLCAYHVQPRPL (SEQ ID NO: 16); or the amino acid sequence of QNLNHYIQVLENLVRSVPS (SEQ ID NO: 9); or a peptide having an amino acid sequence that is different from the amino acid sequence of the former peptide in that 1 to 3 amino acids are substituted, deleted or added and being capable of activating a helper T-cell, as well as products relating to the peptide such as an polynucleotide. The disclosure also provides use of the peptide and the products as a medicament or a composition for activating a helper T-cell.
More Like This:
| WO/2002/072825 | HUMAN MRP5-LIKE PROTEIN |
| WO/1999/064588 | TGF$g(b) RII RECEPTOR NUCLEIC SEQUENCE, CODED PEPTIDE, AND USES |
Inventors:
Noriyuki Ohguri
Kosaka Zhu
Hiroya Kobayashi
Kosaka Zhu
Hiroya Kobayashi
Application Number:
JP2020500589A
Publication Date:
April 14, 2021
Filing Date:
February 15, 2019
Export Citation:
Assignee:
National University Corporation Asahikawa Medical University
International Classes:
C12N15/12; A61K31/7088; A61K35/17; A61K38/08; A61K38/10; A61K38/16; A61K39/00; A61K45/00; A61P35/00; C07K7/06; C07K7/08; C07K14/47; C07K14/74; C12N5/0783; C12N5/09; C12N9/99; C12N15/85
Domestic Patent References:
| JP2016525124A |
Foreign References:
| WO2017194170A1 | ||||
| US20050250137 | ||||
| WO2016156202A1 | ||||
| WO2016187508A2 |
Other References:
ISHIBASHI K et al.,Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor,Oncoimmunology,2016年,Vol.5, No.6,e1169356,ABSTRACT
宮川清,放射線障害に基づく固形がん発生の分子機構の解明とその予防・治療への応用に関する研究 化学療法感受性を,放射線障害に基づく固形がん発生の分子機構の解明とその予防・治療への応用に関する研究 平成21年度 総括・,2010年,pp.47-50,要約
NIEMEYER P et al.,Expression of serologically identified tumor antigens in acute leukemias,Leuk. Res.,2003年,Vol.27, No.7,pp.655-660,Abstract
MAZZONE R et al.,Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy,Clin. Epigenetics,2017年,Vol.9,59,Abstract
宮川清,放射線障害に基づく固形がん発生の分子機構の解明とその予防・治療への応用に関する研究 化学療法感受性を,放射線障害に基づく固形がん発生の分子機構の解明とその予防・治療への応用に関する研究 平成21年度 総括・,2010年,pp.47-50,要約
NIEMEYER P et al.,Expression of serologically identified tumor antigens in acute leukemias,Leuk. Res.,2003年,Vol.27, No.7,pp.655-660,Abstract
MAZZONE R et al.,Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy,Clin. Epigenetics,2017年,Vol.9,59,Abstract
Attorney, Agent or Firm:
Norihito Yamao
Michiko Matsutani
Sakurai Yoko
Keiji Sakata
Michiko Matsutani
Sakurai Yoko
Keiji Sakata